Abstract Presented at ASCO 2025 Annual Meeting Features Two-Month Data from the Largest Randomized Trial Ever Conducted Among Head and Neck Cancer Survivors

MINNEAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the presentation of new clinical data at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting that demonstrates significant clinical and quality-of-life benefits associated with use of the Company’s Flexitouch Plus versus usual care in treating patients with head and neck cancer-related lymphedema.

“Current modalities for managing head and neck cancer-related lymphedema include therapist guided lymphedema treatment and lifelong home-based self-care. However, data shows that patients face substantial barriers to accessing these modalities, which limits the number of patients receiving treatment and delaying therapy initiation for those who do,” said Principal Investigator, Barbara Murphy, MD, Professor of Medicine, Director, Head and Neck Research Program, and Director, Pain and Symptom Management Program at Vanderbilt-Ingram Cancer Center. “Our study found that advanced pneumatic pump technology provides a feasible alternative that reduces swelling, increases speed to initial therapy, and generates strong quality-of-life outcomes.”

The two-month analysis featured data from the Company’s six-month clinical trial, which examines the effectiveness of Flexitouch Plus, an advanced pneumatic compression device (APCD), versus usual care in treating lymphedema among head and neck cancer survivors. The study includes 236 subjects across 10 academic and community sites, representing the largest prospective, randomized controlled study on this patient group ever conducted in the United States. Outcome measures include changes in disease-specific patient-reported symptom survey scores and objective clinical assessments, including CT imaging.

Two-month data demonstrated that usual care and APCD are similarly effective treatment modalities for head and neck lymphedema. Specific areas of differentiation showed:

• Usual care participants took an average of 29.8 days to begin therapist guided lymphedema treatment (TGLT), while APCD participants received their device in 17.9 days;

• Of participants randomized to usual care, only 71% received TGLT compared to 94.9% of those in the APCD group;

• APCD participants had significant reduction in swelling via digital photography and total Head and Neck Cancer Related Lymphedema and Fibrosis Grading (HN-LEFG) scores while usual care participants exhibited marginal improvements; and

• Self-reported symptom improvement occurred in both groups, with APCD demonstrating significant improvement on three of the six health-related quality-of-life sub scales.